v3.26.1
Condensed Consolidated Statements of Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenues    
Total revenues $ 207,705 $ 149,824
Costs and expenses    
Cost of revenues [1] 23,391 15,763
Research and development 39,438 26,927
Selling, general and administrative 125,173 89,944
Amortization of intangible assets 25,644 19,786
Contingent consideration loss 2,391 7,660
Total costs and expenses 216,037 160,080
Operating loss (8,332) (10,256)
Other income (expense)    
Interest and other income, net 2,382 4,425
Total other income (expense), net 2,382 4,425
Loss before income taxes (5,950) (5,831)
Income tax expense (benefit) (3,657) 5,996
Net loss $ (2,293) $ (11,827)
Loss per share    
Basic (in dollars per share) $ (0.04) $ (0.21)
Diluted (in dollars per share) $ (0.04) $ (0.21)
Weighted average shares outstanding    
Basic (in shares) 57,647,548 55,864,692
Diluted (in shares) 57,647,548 55,864,692
Net product sales    
Revenues    
Total revenues $ 150,753 $ 141,988
Collaboration revenue (ZURZUVAE)    
Revenues    
Total revenues 27,643 0
Royalty, licensing, and other revenues    
Revenues    
Total revenues $ 29,309 $ 7,836
[1] Excludes amortization of intangible assets